Blood Based Early Breast Cancer Assay ‘Mastocheck®’, Entry to APAC Region Starting with Singapore > BERTIS NEWS


NEWSROOM

Read latest news from Bertis

BERTIS NEWS

BERTIS NEWS

Blood Based Early Breast Cancer Assay ‘Mastocheck®’, Entry to APAC Region Starting with Singapore

Date 2022.09.26

Hit 810

News

Contracted with one of the largest medical groups in Singapore…Gained a foothold into the Asian market

Blood Based Early Breast Cancer Assay ‘Mastocheck®’,
Entry to APAC Region Starting with Singapore

 

 

- Contract signed regarding Mastocheck® supply agreement with the one of the largest medical groups in Singapore, Raffles Medical Group (RMG), with future plans to distribute to RMG’s overseas medical facilities in China, Japan, Cambodia, and Vietnam

- CEO of Bertis, Seungman Han mentioned, “Going to focus on expanding the overseas deployment, enabling many people to benefit from proteomic-based diagnostic solutions”

 

Bertis (CEO Dongyoung Noh, Seungman Han), a proteomic-based precision medicine technology developing company, announced on 26 that Bertis has signed a contract with one of Singapore’s largest medical groups, Raffles Medical Group (RMG), to supply blood-based early breast cancer assay, Mastocheck®.

 

Through this contract, Mastocheck® will be introduced at Raffles Breast Centre, Raffles Health Screeners, and over 30 Raffles Medical clinics in Singapore, with future plans to distribute to RMG’s overseas medical facilities in China, Japan, Cambodia, and Vietnam. RMG is a leading private healthcare provider in Asia, operating four hospitals and over 100 medical clinics across 14 cities in Asia. Established in 1976, RMG has over 2,700 employees and it provides a seamless and continuum of care to more than 2 million patients annually.

 

< Medical Director of Raffles Medical Group, Dr. Chng Shih Kiat(Left) and CEO of Bertis, Seungman Han (Right) are taking a commemorative photo after signing a Mastocheck® supply contract on Sept 26>

 

Mastocheck® is the world’s first blood-based early breast cancer assay using proteomics technology developed by Bertis. It diagnoses breast cancer by inputting the quantified values of breast cancer-specific protein biomarkers from the blood into a unique algorithm. Mastocheck® was approved as an in vitro diagnostic device by the Ministry of Food and Drug Safety, known as KFDA in January 2019 after providing its efficacy in diagnosing stage 0-2 stage breast cancer.

 

Asian women, including Koreans, have a higher proportion of dense breasts than Western women. In the case of dense breast, the density of mammary gland tissue is higher than that of adipose tissue, so the tumor may not be visible during the Breast X-ray, Mammography. Mastocheck® is a blood-based assay that shows high accuracy even in dense breast women. Since blood-based assay does not depend on reader’s subjective judgment, it shows consistent and accurate result at all times. It also can apply to younger women, and pregnant women.

 

CEO of Bertis, Seungman Han said “Proteomic technology has the advantage of providing accurate and convenient high-quality tests at an affordable price. And we will do our best to expand the Mastocheck® availability to other regions, including Asia so that more people can benefit from the proteomic-based diagnostic assay.”

 

Dr. Chng Shih Kiat, Medical Director of Raffles Medical said “Breast cancer is the most common cancer in women, and early detection can save lives. As part of our continued effort to improve patient care, Mastocheck® is offered at Raffles Breast Centre, Raffles Health Screeners, and over 30 of our GP clinics to serve our patients’ evolving healthcare and wellness needs.”

 

Bertis is also a representative company in the clinical proteomics field that successfully commercialized breast cancer assay by combining proteomics and bioinformatics. In October 2021, Bertis Bioscience, a U.S. corporation, was established and its San Diego laboratory was opened in April 2022.


go top